A Multicenter, Non-inferiority, Phase 3, Randomized Controlled Study of Moderated Hypofractionated Online Adaptive Radiotherapy for Cervical Cancer
The most common external beam radiotherapy fractionation scheme for cervical cancer is 45-50.4 Gy delivered in 25-28 fractions. However, prolonged treatment duration can lead to insufficient availability of medical resources. We hope to assess the safety and efficacy of moderated hypofractionated online adaptive radiotherapy in combination with brachytherapy in patients with cervical cancer in a multicenter study.
• The patient is fully voluntary and has the capacity for autonomy, signing the informed consent form 30 days prior to enrollment
• Age ≥18 and ≤75 years
• FIGO stage IB-IIIB cervical cancer; IIIC1 (lymph node metastasis ≤2 cm, without common iliac lymph node metastasis)
• Pathologically diagnosed as squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
• Concurrent weekly cisplatin therapy ± immunotherapy
• Able to undergo brachytherapy
• ECOG performance status of 0-1, with an expected ability to tolerate lying flat for half an hour.